News
IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...
With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
3don MSN
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer
Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...
The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...
Clinical Trials Arena on MSN3d
Perioperative Padcev and Keytruda improves survival in MIBC
P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback